Propanc Biopharma's S-1 details 1:25 reverse split and Hexstone resale terms
The filing shows shares outstanding fell to about 3.5 million after a May reverse split, with continued going concern and default disclosures.
SEC filing
Latest
2 stories
Friday, July 17
Tuesday, July 14
Propanc Biopharma board member departs, accountant Carlo Campiciano appointed to replace her
Annie Van Broekhoven retired from Propanc's board effective July 8, 2026, and the board named Carlo Campiciano to fill the vacancy.
SEC filing